drugset
drugset / Trial / NCT00388362

Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease

NCT00388362 ↗

Phase 2 Completed 36 enrolled Stanford University
NaSingle-groupOpen-labelTreatment

Summary

To study the effectiveness of an immunosuppressive drug sirolimus, in the treatment of chronic graft versus host disease in combination with prednisone.

Timeline

Start
2005-11
Primary completion
2010-11
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule 2 mg Oral
Background Prednisone Other / unclassified — —

Indications

chronic graft versus host disease